Tag Archives: AIM

GWPH Phase 3 Results

GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress

GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress

LONDON, Aug. 9, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the third quarter ended 30 June 2016.

GWPH Phase 3 Results

GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising $289.8 Million on the NASDAQ Global Market and Full Exercise of Underwriter’s Option to Purchase Additional ADSs

LONDON, July 18, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced offering on the NASDAQ Global Market.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference and the Jefferies 2016 Healthcare Conference

LONDON, May 31, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Goldman Sachs 37th Annual Global Healthcare Conference.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May

LONDON, May 16, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016, at 8:00 a.m. (EDT) at the Grand Hyatt Hotel in New York City.

GWPH Phase 3 Results

GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress

LONDON, May 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter and half-year ended 31 March 2016.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 May

LONDON, May 4, 2016 /Weed Wire/ — GW Pharmaceuticals announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016, at 9:20 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev.


Top